EnteroMedics (ETRM) has an average broker rating of 2, which is interpreted as a Buy, as rated by 2 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Shares of EnteroMedics Inc. appreciated by 12.67% during the last five trading days but lost 6.65% on a 4-week basis. EnteroMedics Inc. has dropped 73.69% during the last 3-month period . Year-to-Date the stock performance stands at -90.42%. EnteroMedics (NASDAQ:ETRM): stock turned positive on Tuesday. Though the stock opened at $0.189, the bulls momentum made the stock top out at $0.192 level for the day. The stock recorded a low of $0.1805 and closed the trading day at $0.1868, in the green by 3.72%. The total traded volume for the day was 8,132,146. The stock had closed at $0.1801 in the previous days trading.
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Companys neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Companys initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.